CytomX Therapeutics, Inc. announced the appointment of Charles Fuchs, M.D., M.P.H., to its Board of Directors as a Class II director, effective July 24, 2026. Dr. Fuchs will receive standard non-employee director compensation and an option to purchase 118,000 shares of common stock under the 2015 Equity Incentive Plan. CytomX Therapeutics, Inc. is a biotechnology company focused on developing clinical-stage therapeutics.
